KYMR Insider Trading Activity and SEC Form 4 Filings
KYMR insider trading summary
Over the past 12 months, insiders at Kymera Therapeutics, Inc. (KYMR) reported 212 sales worth $219.7M by 10 insiders and 12 open-market purchases worth $1.03B by 6 insiders on SEC Form 4. Net insider buying was $815.3M.
Latest KYMR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Nello Mainolfi | Chief Executive Officer | Sell | $552K (4,876 @ $113.24) |
| Oct 1, 2026 | Nello Mainolfi | Chief Executive Officer | Sell | $619K (5,506 @ $112.42) |
| Oct 1, 2026 | Nello Mainolfi | Chief Executive Officer | Sell | $950K (8,230 @ $115.40) |
| Oct 1, 2026 | Nello Mainolfi | Chief Executive Officer | Sell | $870K (7,601 @ $114.43) |
| Oct 1, 2026 | Nello Mainolfi | Chief Executive Officer | Sell | $30K (262 @ $116.12) |
| Oct 1, 2026 | Nello Mainolfi | Chief Executive Officer | Sell | $393K (3,525 @ $111.44) |
| Sep 4, 2026 | Brian Adams | Chief Legal Officer | Sell | $353K (3,025 @ $116.81) |
| Sep 4, 2026 | Brian Adams | Chief Legal Officer | Sell | $251K (2,137 @ $117.57) |
| Sep 4, 2026 | Brian Adams | Chief Legal Officer | Sell | $140K (1,209 @ $115.55) |
| Jul 7, 2026 | Nello Mainolfi | Chief Executive Officer | Sell | $6.0M (50,000 @ $119.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.